Premium
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel‐Group, Randomized, Placebo‐controlled Clinical Trials
Author(s) -
Markman John D.,
Jensen Troels Staehelin,
Semel David,
Li Chunming,
Parsons Bruce,
Behar Regina,
Sadosky Alesia B.
Publication year - 2017
Publication title -
pain practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.899
H-Index - 58
eISSN - 1533-2500
pISSN - 1530-7085
DOI - 10.1111/papr.12516
Subject(s) - pregabalin , gabapentin , medicine , placebo , neuropathic pain , anesthesia , randomized controlled trial , placebo group , clinical trial , physical therapy , alternative medicine , pathology
Objectives This analysis compared the therapeutic response of pregabalin in patients with neuropathic pain (NeP) who had been previously treated with gabapentin to the therapeutic response in patients who had not received gabapentin previously. Methods Data were pooled from 18 randomized, double‐blind, placebo‐controlled trials of pregabalin in patients with NeP. Pregabalin‐mediated changes in pain and pain‐related sleep interference scores, patient global impression of change scores at endpoint, and the occurrence of adverse events were compared between patients who had received gabapentin previously (+ GBN ) and patients who had not received gabapentin previously (− GBN ). Results There were no significant differences between the − GBN and + GBN cohorts with regard to the extent of pain relief and relief of pain‐related sleep interference for any dose of pregabalin (150, 300, 600, or 150 to 600 mg/day) at any time point (6, 8, or 12 weeks). Additionally, there was no significant difference in the distribution of patient global impression of change scores at study endpoint, or the occurrence of adverse events, between the − GBN and + GBN cohorts. Discussion The findings presented here support the idea that pregabalin may be used successfully to treat patients with NeP who may be refractory, respond inadequately, or are intolerant to gabapentin. These findings highlight the importance of tailoring treatment of NeP based on individual patient response to different treatments, including the trial of multiple agents within the same mechanistic class.